Docoh
Loading...

87 results

Filter options loading...
Top filers
Top filing types
Recent filing years
8-K
EX-1.1
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
effective by the Commission under the Securities Act. The Company has complied to the Commission’s satisfaction with all requests of the Commission … reasonable judgment, and to the continuing satisfaction (or waiver by the Sales Agent in its sole discretion) of the following additional conditions
8-K
EX-5.1
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
identified to our satisfaction, of such records and documents of the Company, certificates of officers, directors and representatives of the Company
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
of Confidential Information or related competitive harm to the reasonable satisfaction of Ocuphire. In addition, Processa will consider in good faith any … to the reasonable satisfaction of Processa, and reasonably considers any timely comments provided by Processa with respect to such publication or public
DEF 14A
PCSA Processa Pharmaceuticals Inc
22 Apr 21
Definitive proxy
2:00pm
on capital; return on assets; operating working capital; average accounts receivable; economic value added; total stockholder return; customer satisfaction … ; customer satisfaction; operating margin; profit margin; sales performance; sales quota attainment; new sales; cross/integrated sales; customer engagement
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA’s satisfaction, the FDA will typically … not be observed in human clinical trials. If clinical trials of our planned product candidates fail to demonstrate efficacy to the satisfaction of regulatory
8-K
EX-10.1
fmc1cmu9 w3ta
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-99.1
goeshkp muveiohxyu
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-10.3
ut4cmb 4fgtaistb
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
fio43m
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
10-Q
myld5xwompmc
12 Nov 20
Quarterly report
4:01pm
8-K
EX-99.1
ifbyy8qlbz gfkds
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
8-K
EX-1.1
9i65mefj3n16pr4ko9
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
424B4
1fy3lit5weovu5 ll3
5 Oct 20
Prospectus supplement with pricing info
4:16pm
S-1/A
4v6 159q97
30 Sep 20
IPO registration (amended)
4:06pm
S-1/A
EX-5.1
u7et59ot8 a2zd7zwq
30 Sep 20
IPO registration (amended)
4:06pm
S-1/A
kevs9b3 weg
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-2.1
f4uvurqyqauuj
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-4.3
exj106barus 8tzo
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-1.1
emrgt lwvmsk6op5s
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-10.5
wdg4zp
16 Sep 20
IPO registration (amended)
8:00pm